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BSTRACT
 
Background
 
In patients with refractory unstable
angina, the platelet glycoprotein IIb/IIIa–receptor an-
tibody abciximab reduces the incidence of cardiac
events before and during coronary angioplasty. We
investigated whether serum troponin T levels identi-
fy patients most likely to benefit from therapy with
this drug.
 
Methods
 
Among 1265 patients with unstable angi-
na who were enrolled in the c7E3 Fab Antiplatelet
Therapy in Unstable Refractory Angina (CAPTURE)
trial, serum samples drawn at the time of randomiza-
tion to abciximab or placebo were available from 890
patients; we used these samples for the determina-
tion of troponin T and creatine kinase MB levels. Pa-
tients with postinfarction angina were not included.
 
Results
 
Serum troponin T levels at the time of
study entry were elevated (above 0.1 ng per milliliter)
in 275 patients (30.9 percent). Among patients re-
ceiving placebo, the risk of death or nonfatal myo-
cardial infarction was related to troponin T levels.
The six-month cumulative event rate was 23.9 per-
cent among patients with elevated troponin T levels,
as compared with 7.5 percent among patients with-
out elevated troponin T levels (P<0.001). Among
patients treated with abciximab, the respective six-
month event rates were 9.5 percent for patients with
elevated troponin T levels and 9.4 percent for those
without elevated levels. As compared with placebo,
the relative risk of death or nonfatal myocardial in-
farction associated with treatment with abciximab in
patients with elevated troponin T levels was 0.32 (95
percent confidence interval, 0.14 to 0.62; P=0.002).
The lower event rates in patients receiving abcix-
imab were attributable to a reduction in the rate of
myocardial infarction (odds ratio, 0.23; 95 percent
confidence interval, 0.12 to 0.49; P<0.001). In pa-
tients without elevated troponin T levels, there was
no benefit of treatment with respect to the relative
risk of death or myocardial infarction at six months
(odds ratio, 1.26; 95 percent confidence interval, 0.74
to 2.31; P=0.47).
 
Conclusions
 
The serum troponin T level, which is
considered to be a surrogate marker for thrombus
formation, identifies a high-risk subgroup of patients
with refractory unstable angina suitable for coronary
angioplasty who will particularly benefit from anti-
platelet treatment with abciximab. (N Engl J Med
1999;340:1623-9.)
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NSTABLE angina is a critical phase of
coronary heart disease that is defined by
clinical symptoms and is associated with
a high risk of myocardial infarction and
death.
 
1
 
 The underlying pathophysiologic mechanism
involves rupture or erosion of atherosclerotic plaques,
followed by local thrombus formation.
 
2-4
 
 If throm-
botic material is transported downstream, focal cell
necrosis will result.
 
3
 
 Such minor myocardial injury is
detected in 20 to 40 percent of patients with unsta-
ble angina by the measurement of serum troponin
T or troponin I, but rarely by measurement of se-
rum creatine kinase.
 
5-12
 
 Patients with such minor
myocardial injury are at increased risk for adverse
outcomes — in particular, subsequent myocardial
infarction or sudden death.
 
6-15
 
The recent c7E3 Fab Antiplatelet Therapy in Un-
stable Refractory Angina (CAPTURE) trial dem-
onstrated that treatment with the glycoprotein
IIb/IIIa–receptor blocker abciximab reduced the
risk of myocardial infarction in patients with refrac-
tory unstable angina, both during the 18-to-24-hour
period preceding the coronary intervention and dur-
ing subsequent balloon angioplasty.
 
16
 
 Since treat-
ment with abciximab is directed against the forma-
tion of platelet aggregates, we postulated that such
treatment might be particularly effective in patients
with elevated troponin T levels due to thrombotic
microembolization. Accordingly, we assessed the val-
ue of troponin T measurements taken at base line
among patients in the CAPTURE study in predict-
ing the therapeutic efficacy of abciximab.
 
METHODS
 
Patients
 
The study population of the CAPTURE trial was composed of
1265 patients (345 women and 920 men; mean [±SD] age,
U
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61±10 years) who were recruited from 69 centers in 12 countries
between May 1993 and December 1995. All the patients had had
recurrent chest pain at rest, with concomitant electrocardiograph-
ic changes (ST-segment depression, ST-segment elevation, or ab-
normal T waves), and had had one or more episodes of chest pain
or electrocardiographic abnormalities, or both, within two hours
after the initiation of therapy with intravenous heparin and nitro-
glycerin. The most recent episode of ischemia had to have oc-
curred within 48 hours before randomization (mean, 8.7±6.0).
Exclusion criteria were the occurrence of a recent myocardial in-
farction, unless serum creatine kinase (CK) enzyme activity had
returned to less than two times the upper limit of normal; the
need for immediate intervention; and the presence of risk factors
for bleeding. All patients had evidence on coronary angiography
of substantial coronary artery disease (defined by the presence of
one culprit lesion suitable for angioplasty). Study medication was
started within 24 hours after angiography, and percutaneous
transluminal coronary angioplasty (PTCA) was scheduled to be
performed 18 to 24 hours after the start of study medication. Ad-
ditional electrocardiograms were recorded at enrollment; 6, 12,
and 18 hours after enrollment; just before PTCA; 1, 6, and 24
hours after PTCA; at discharge; and whenever patients had recur-
rent chest pain. Further details have been published elsewhere.
 
16
 
Patients were randomly assigned to receive a bolus injection of
0.25 mg of abciximab (ReoPro, Centocor, Leiden, the Nether-
lands, and Eli Lilly, Indianapolis) per kilogram of body weight,
followed by a continuous infusion at a rate of 10 µg per minute,
or to receive a matching placebo. Treatment was started within
two hours after randomization and continued until one hour af-
ter the completion of PTCA.
During hospitalization and the six-month follow-up period, all
events were recorded, including death, nonfatal myocardial infarc-
tion, repeated PTCA, and coronary bypass surgery. Myocardial
infarction was diagnosed during the index hospital stay, which in-
cluded the angioplasty procedure, when the level of CK activity
was more than three times the upper limit of normal in at least
two samples or when new, clinically significant Q waves were de-
tected in two or more continuous electrocardiographic leads. My-
ocardial infarction after discharge was diagnosed on the basis of
CK values exceeding two times the upper limit of normal or the
detection of new, significant Q waves in two or more continuous
leads. With respect to rates of cardiac events, four time points
were considered: the period before PTCA (up to 36 hours after
randomization), 72 hours after randomization (including up to
36 hours after PTCA), 30 days after randomization, and 6 months
after randomization.
 
Analytic Techniques
 
All serum samples were stored at –20°C or lower and trans-
ported to a central laboratory, where they were stored at –80°C
until they were analyzed. Quantitative determination of the
cardiac markers (troponin T and creatine kinase MB fraction
[CK-MB]) was performed at the research laboratory of the Univer-
sity of Hamburg by technicians who were unaware of the patients’
histories and the assigned treatments.
Serum cardiac troponin T was measured with a one-step en-
zyme immunoassay that uses magnetic particles carrying the mon-
oclonal antibody and chemiluminescence (Elecsys 2010, Boeh-
ringer Mannheim, Mannheim, Germany). The lower limit of
detection in this assay was 0.01 ng per milliliter, and the threshold
value for the diagnosis (the diagnostic cutoff point) was 0.10 ng
per milliliter.
 
17
 
 The interassay coefficient of variation was 6.7 per-
cent at a level of 0.12 ng per milliliter and 4.1 percent at 0.56 ng
per milliliter with internal controls.
Serum CK-MB levels were determined in parallel with mono-
clonal antibodies by the same analyzer. The lower limit of detec-
tion in this assay was 0.15 ng per milliliter, and the upper reference
(cutoff ) level was 5.0 ng per milliliter. The interassay coefficient of
variation was 8.4 percent at a level of 8.2 ng per milliliter and 7.2
percent at 14.7 ng per milliliter with internal controls.
 
Statistical Analysis
 
To distinguish among patients who derived different degrees of
benefit from treatment with abciximab, an exploratory data analy-
sis was chosen.
 
18
 
 Patients with measurable troponin T levels
(>0.01 ng per milliliter) were grouped into quartiles of approxi-
mately 130 patients each. For each of the four time points, a lo-
gistic-regression analysis was performed. The treatment was in-
cluded in the model equation as a binary variable and was coded
as 0 (placebo) or 1 (abciximab). For troponin T values, we used
four dichotomous indicator variables to represent the ranges
within each quartile (0.02 to 0.04 ng per milliliter, 0.05 to 0.12
ng per milliliter, 0.13 to 0.32 ng per milliliter, and >0.32 ng per
milliliter). Patients with troponin T values at or below 0.01 ng
per milliliter served as the reference group.
To assess a possible interaction between troponin T levels and
the therapeutic benefit of abciximab, terms denoting the interac-
tion between troponin T and treatment were incorporated into
the model. The model was fitted with and without the interac-
tion terms. If the introduction of the interaction terms improved
the fit of the model, the likelihood-ratio test with four degrees of
freedom should have indicated statistical significance. The dem-
onstration of an interaction implied differing degrees of benefit
with abciximab at various troponin T levels.
In addition, the troponin T levels (>0.1 vs. «0.1 ng per mil-
liliter), CK-MB levels (>5.0 vs. «5.0 ng per milliliter), and elec-
trocardiographic findings (presence vs. absence) were coded as di-
chotomous variables. Reverse stepwise logistic-regression analysis
was used to identify variables with independent predictive value
for the therapeutic benefit of abciximab.
Continuous variables were expressed as means ±SD, and com-
parisons between two subgroups were performed with the Mann–
Whitney U test (two-sided). P values below 0.05 were considered
to indicate statistical significance. Comparisons of categorical var-
iables were performed with Fisher’s exact test (two-sided). All cal-
culations were performed with SPSS version 7.5 (SPSS, Chicago)
or StatXact 3 (Cytel Software, Cambridge, Mass.) software.
 
RESULTS
 
Among 1265 patients enrolled in the CAPTURE
trial, 198 patients were excluded from the analysis
because they had myocardial infarctions within 14
days before enrollment. Serum troponin T levels
may be elevated for up to 14 days after myocardial
infarction, and high values therefore do not neces-
sarily reflect minor myocardial damage in these pa-
tients.
 
5
 
 The results of the analyses of the serum sam-
ples obtained at the time of randomization were
available for 890 of the remaining 1067 patients (83
percent).
The base-line characteristics of these 890 patients
were similar to those of the total study population
with respect to age, sex, cardiovascular-risk profile,
and concomitant treatment before and after ran-
domization. During the six months of follow-up, 19
deaths were recorded and 79 patients had nonfatal
myocardial infarctions. The degree of reduction in
the incidence of cardiac events among the 890 pa-
tients in the current analysis was similar to that in
the entire CAPTURE study population before PTCA
(event rate, 2.4 percent among those receiving pla-
cebo vs. 0.9 percent among those receiving abcix-
imab; P=0.12), 72 hours after randomization (8.3
percent vs. 4.3 percent, P=0.02), and 30 days after
randomization (9.4 percent vs. 5.4 percent, P=0.012).
Copyright © 1999 Massachusetts Medical Society. All rights reserved. 
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The absolute difference in event rates in the two
treatment groups was fairly consistent during the
six-month follow-up; at six months this difference
was 4.3 percentage points, although it was no longer
significant (12.9 percent vs. 8.6 percent, P=0.14).
 
Interaction between Serum Troponin T Level and the 
Therapeutic Benefit of Abciximab
 
To characterize a possible relation between base-
line serum troponin T levels and the benefit of treat-
ment with abciximab, the patients were categorized
according to troponin T level (Table 1). Troponin T
was not detectable in 372 patients (41.8 percent) —
182 receiving placebo and 190 receiving abciximab.
In these patients, the event rates did not differ sig-
nificantly between the placebo and abciximab groups
during the 36 hours before PTCA (0 vs. 0.5 per-
cent, P=1.00). Although there was a trend toward
reduced events during the period up to 72 hours af-
ter randomization for the patients receiving abcix-
imab (4.9 percent vs. 2.1 percent, P=0.17), this dif-
ference was not as apparent at 30 days (4.9 percent
vs. 2.6 percent, P=0.28) or after 6 months of fol-
low-up (6.6 percent vs. 6.3 percent, P=1.00).
Troponin T was detectable in base-line serum sam-
ples of 518 patients (58.2 percent). Patients were
stratified into quartiles according to the level of tropo-
nin T measured: 0.02 to 0.04 ng per milliliter (138
patients), 0.05 to 0.12 ng per milliliter (129 patients),
0.13 to 0.32 ng per milliliter (123 patients), and
>0.32 ng per milliliter (128 patients). Table 1 shows
that in patients with troponin T levels of 0.12 ng per
milliliter or less, event rates were low and did not
differ significantly between those receiving abcix-
imab and those receiving placebo at all four time
points. In contrast, for patients with troponin T lev-
els above 0.12 ng per milliliter, the risk of a cardiac
event was higher in the placebo group than at lower
levels, whereas event rates remained essentially un-
changed when patients were treated with abciximab.
This interaction between the therapeutic benefit of
abciximab and the troponin T level was statistically
significant at 72 hours, 30 days, and 6 months of fol-
low-up. The therapeutic benefit of abciximab in the
CAPTURE trial was evident in the two upper quar-
tiles of patients, with troponin T values higher than
0.12 ng per milliliter (Fig. 1).
 
Stratification According to Serum Troponin T Level
 
Since the therapeutic cutoff level we identified for
serum troponin T is close to the diagnostic cutoff
level of 0.1 ng per milliliter, which is widely used in
clinical practice, we analyzed the data according to
this cutoff level. The base-line characteristics of the
275 patients (30.9 percent) above the cutoff level
(those considered to be troponin T–positive) and
the 615 patients below this level (those considered
to be troponin T–negative) are presented in Table 2.
 
*Events were defined as nonfatal myocardial infarction and death.
†The numbers of patients in each treatment group were as follows: tro-
ponin T level «0.01 ng per milliliter: placebo, 182; abciximab, 190; tro-
ponin T level 0.02 to 0.04 ng per milliliter: placebo, 68; abciximab, 70;
troponin T level 0.05 to 0.12 ng per milliliter: placebo, 68; abciximab, 61;
troponin T level 0.13 to 0.32 ng per milliliter: placebo, 63; abciximab, 60;
troponin T level >0.32 ng per milliliter: placebo, 64; abciximab, 64.
‡PTCA denotes percutaneous transluminal coronary angioplasty. Except
for “before PTCA,” times listed are after randomization.
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Figure 1.
 
 Odds Ratios for Cardiac Events Associated with Treat-
ment with Abciximab at the Six-Month Follow-up, According to
Quartile of Serum Troponin T.
Cardiac events were death and nonfatal myocardial infarction.
P values are for the comparison with the placebo group. Verti-
cal bars represent 95 percent confidence intervals.
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*Plus–minus values are means ±SD.
†PTCA denotes percutaneous transluminal coronary angioplasty, and CABG coronary-artery
bypass graft.
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Figure 2.
 
 Rates of Cardiac Events in the Initial 72 Hours after Randomization (Panel A) and during the 6 Months of Follow-up (Panel
B) among Patients with Serum Troponin T Levels above and Those with Levels below the Diagnostic Cutoff Point.
Cardiac events were death and nonfatal myocardial infarction. Percutaneous transluminal coronary angioplasty was performed
18 to 24 hours after randomization.
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There were no significant differences between these
groups.
Cardiac events (death or nonfatal myocardial in-
farction) are shown according to troponin T level
and the randomly assigned treatment group in Fig-
ure 2. Among the troponin T–negative patients who
were receiving placebo, events during the 36 hours
before PTCA were infrequent (0.7 percent), where-
as events occurred in association with the procedure
(within 72 hours after randomization) in 3.5 percent
of patients. Only a few additional events were re-
corded in the subsequent six months of follow-up,
resulting in a total event rate of 7.5 percent (odds ra-
tio, 1.26; 95 percent confidence interval, 0.74 to
2.31; P=0.47). There were no significant differences
in event rates between the placebo and abciximab
groups at any of the four time points (Table 3).
In contrast, the event rates for troponin T–posi-
tive patients who were receiving placebo were high
— both before PTCA (6.6 percent) and in associa-
tion with PTCA (10.8 percent), as well as during
the subsequent period after discharge, resulting in
a total event rate of 23.9 percent at six months
(P<0.001 for comparison with troponin T–nega-
tive patients). The rates of events occurring before
and in association with PTCA were reduced by
treatment with abciximab — to 0.7 percent before
PTCA (odds ratio, 0.45; 95 percent confidence in-
terval, 0.21 to 0.95; P=0.02) and to 2.9 percent in
the 72 hours after randomization (cumulative event
rate, 3.6 percent; odds ratio, 0.29; 95 percent con-
fidence interval, 0.11 to 0.54; P=0.007). This initial
benefit — an absolute risk reduction of 13.8 per-
centage points at 30 days — was preserved during
the six months of follow-up (cumulative event rates,
9.5 percent for the abciximab group vs. 23.9 percent
for the placebo group; odds ratio, 0.32; 95 percent
confidence interval, 0.14 to 0.62; P=0.002).
The risk of cardiac events among the troponin
T–positive patients treated with abciximab was sim-
ilar to that observed among the troponin T–nega-
tive patients (Table 3). The lower event rates were
attributable to a reduction in the rate of myocardial
infarction (odds ratio, 0.23; 95 percent confidence
interval, 0.12 to 0.49; P<0.001). Total mortality in
the CAPTURE trial was low, 0.8 percent at 30 days
and 2.1 percent at 6 months. Among the troponin
T–positive patients, mortality in the placebo group
was 3.6 percent and did not differ significantly from
that in the abciximab group (2.9 percent, P=0.74).
 
Serum CK-MB Level
 
At the time of study entry, the CK-MB value was
above the cutoff level of 5.0 ng per milliliter in 116
patients (13.0 percent; 63 receiving placebo and 53
receiving abciximab). The mean value was 8.7±6.2
ng per milliliter (range, 5.0 to 36.5).
The presence of an elevated CK-MB level was a
significant predictor of an increased risk of cardiac
events at all time points. However, a regression
analysis that included a term for interaction indicat-
ed no significant relation between the CK-MB level
and the benefit of treatment with abciximab. This
lack of relation was consistent regardless of CK-MB
level or time point. At the six-month follow-up,
there was no significant benefit of abciximab treat-
ment, either among the patients with CK-MB levels
above 5.0 ng per milliliter (odds ratio, 0.63; 95 per-
cent confidence interval, 0.28 to 1.24; P=0.11) or
among those with normal CK-MB values (odds ra-
tio, 0.75; 95 percent confidence interval, 0.48 to
1.14; P=0.16).
 
*Events were defined as nonfatal myocardial infarction and death. PTCA denotes percutaneous
transluminal coronary angioplasty.
†The mortality rate was for the six-month period after randomization.
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SERUM TROPONIN 
T LEVEL EVENT RATE MORTALITY†
BEFORE
PTCA
72 HR AFTER
RANDOMIZATION
30 DAYS AFTER
RANDOMIZATION
6 MO AFTER 
RANDOMIZATION
percent
«0.1 ng/ml
Placebo 0.7 4.2 4.9 7.5 1.3
Abciximab 1.0 4.5 5.2 9.4 1.9
P value 1.00 1.00 1.00 0.47 0.75
>0.1 ng/ml
Placebo 6.6 17.4 19.6 23.9 3.6
Abciximab 0.7 3.6 5.8 9.5 2.9
P value 0.02 0.007 0.001 0.002 0.74
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Comparison of Predictive Values
At six months, only troponin T levels above the
diagnostic cutoff level were significant predictive fac-
tors (Fig. 3). In a stepwise logistic-regression model,
the inclusion of the CK-MB level and electrocardio-
graphic findings indicating unstable angina (ST-seg-
ment depression and T-wave inversion) did not have
independent predictive value when troponin T was
forced into the model first.
DISCUSSION
Previous studies of patients with unstable angina
or evolving myocardial infarction without ST-seg-
ment elevation have shown that serum troponin T
and troponin I levels are potent, independent pre-
dictors of the short-term and long-term risk of my-
ocardial infarction and death.6-15 Our findings indi-
cate that patients with refractory unstable angina
and elevated troponin T levels may be treated effec-
tively with glycoprotein IIb/IIIa–receptor blockers.
The CAPTURE trial enrolled patients with re-
fractory unstable angina who were scheduled to un-
dergo PTCA for a single culprit lesion. Treatment
with the glycoprotein IIb/IIIa–receptor blocker ab-
ciximab effectively reduced the risk of myocardial in-
farction both before and during PTCA. This post
hoc analysis of the serum samples collected on study
entry revealed that 30.9 percent of the patients had
elevated levels of circulating troponin T (>0.1 ng
per milliliter), in concordance with other studies.6-15
As in previous studies, the level of troponin T cor-
related with the event rates.9,11 The six-month event
rate in the placebo group was 23.9 percent when
troponin T was elevated, as compared with 7.5 per-
cent when levels were normal (P<0.001). Abcix-
imab reduced this risk to approximately that of pa-
tients with troponin T levels below the diagnostic
cutoff value. The risk reduction brought about by
abciximab was mainly apparent as a reduction in the
rate of myocardial infarction before as well as during
PTCA and was maintained over a period of six
months (odds ratio, 0.32; P=0.002). The CK-MB
level was not predictive of the therapeutic benefit of
abciximab.
These findings may serve as the basis for a new
therapeutic approach to the treatment of high-risk
patients with unstable angina pectoris. High serum
levels of troponin T or troponin I in such patients
reflect an active thrombotic process, with distal em-
bolization of platelet thrombi originating from the
culprit lesion.2,3 Antithrombotic therapy with high
doses of glycoprotein IIb/IIIa–receptor blockers
will reduce the incidence of thrombus formation at
the culprit lesion and may facilitate the resolution of
distal microthrombi. Thus, glycoprotein IIb/IIIa–
receptor blockers provide protection from further
myocardial damage. Our data indicate that this mech-
anism applies to both thrombotic complications aris-
ing from spontaneous plaque disruption (as shown
by the reduction of events before PTCA) and throm-
botic complications associated with the rupture of
plaque induced by PTCA.
The event rate before PTCA and that associated
with PTCA were low among the patients with re-
fractory unstable angina who did not have elevated
troponin T levels and who were receiving placebo.
In contrast, those with troponin T levels above 0.1
ng per milliliter had high rates of events before
PTCA as well as after the procedure; these rates were
effectively reduced by treatment with abciximab.
Treatment of 100 patients with elevated troponin T
levels with abciximab, rather than standard treat-
ment, would prevent 15 cardiac events. Similarly, in
the Fragmin during Instability in Coronary Artery
Disease trial, the benefit of prolonged treatment
with low-molecular-weight heparin was apparent
only in patients with elevated troponin T levels, and
only over a period of 42 days.19 However, the rates
of cardiac events and coronary interventions in that
trial were lower than in the CAPTURE trial.
There are a few limitations to using troponin T
measurements in therapeutic decision making. The
timing of sampling is crucial for accurate interpreta-
tion of troponin T findings. Measuring troponin T
a mean of 8.7 hours after the qualifying episode of
chest pain, as was done in this study, appears ade-
quate, whereas a single measurement obtained on
arrival at the hospital was shown to be inappropriate
for determining risk.10 The absence of detectable
troponin T does not rule out the presence of coro-
nary heart disease, but it does identify a patient at
Figure 3. Odds Ratios for Cardiac Events Associated with Treat-
ment with Abciximab at the Six-Month Follow-up, in Sub-
groups of Patients Defined According to Serum Troponin T
(TnT) Level, Serum Creatine Kinase MB Fraction (CK-MB), ST-
Segment Depression, and T-Wave Inversion.
Vertical bars represent 95 percent confidence intervals. 
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lower risk for cardiac events. Positive tests for tropo-
nin T can also indicate other serious conditions,
such as acute pulmonary embolism or myocarditis,10
but false positive tests are rare.20
In conclusion, troponin T may serve as a surro-
gate marker of active thrombus formation. An ele-
vated troponin T value (>0.1 ng per milliliter) iden-
tifies some patients with unstable angina who are at
high risk for cardiac events both before and after
PTCA and who will benefit the most from treat-
ment with abciximab. Accordingly, this study dem-
onstrates how a new diagnostic test (for detecting
troponin T) and a therapeutic advance (abciximab)
can be combined for the benefit of patients with
acute coronary syndromes.
Presented in part at the 47th Annual Scientific Session of the American
College of Cardiology, Atlanta, March 29–April 1, 1998.
We are indebted to Sabine Wohlrath and Ariane Deu for their ex-
pert technical assistance.
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cia, Barcelona; R. Melgares, Granada; United Kingdom — M. Khan, P.
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CORRECTION
Benefit of Abciximab in Patients with Refractory
Unstable Angina in Relation to Serum Troponin T
Levels
Benefit of Abciximab in Patients with Refractory Unstable Angina in
Relation to Serum Troponin T Levels . On page 1626, the curves in
Figure 2B were mislabeled. The corrected figure appears below.
Corrected Figure.
Corrected Figure.
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